2024-07-29 09:00:13
What will happen to Doliprane? While President Emmanuel Macron has made paracetamol a symbol of the country’s health recovery policy, Sanofi is preparing to say goodbye to the iconic little yellow box it inherited when it absorbed Aventis two decades ago. Enough to create some friction between the government and France’s pharmaceutical leaders.
The laboratory announced in October 2023 that it intended to soon separate from its OTC subsidiary Opella (2023 turnover of 5.2 billion euros), which has about 100 products, including the French pharmacy’s star painkiller .
“We told Sanofi that we did not want them to sell Opera. Despite this, Sanofi maintained the decision to sell”we commented on Bessie, who warned he would watch “In a harsh way” Protect productive capacity on state lands. “Paracetaminophen produced in France must stay in France”we add to the department.
Several acquisition candidates
The speech was reminiscent of that of Servier Laboratories, which plans to sell Biogaran, France’s No. 1 generic drug. “Our project is by no means synonymous with the end of French Doliprane”Sanofi’s financial director, François-Xavier Roger, wanted to reassure them when he presented the group’s half-year results on Thursday, July 25.
READ ALSO | Article reserved for our subscribers Biogaran: Legislative elections complicate sales of French generic flagship product
Add to your selection
To resolve the dispute, Sanofi will consider gaining a foothold in its subsidiary by retaining a significant minority stake in Opella Capital. If sold to a private company (another envisioned scenario is an initial public offering), the lab could retain 30% or nearly 50% of the capital in its consumer health division, depending on research options.
READ ALSO | Article reserved for our subscribers Paracetamol made in France, a question of sovereignty
Add to your selection
The lab has yet to decide on the terms of its subsidiary’s departure, but the latter appears to have piqued interest. “The good news is that the process between these different options is very competitive regardless.””, Mr. Roger emphasized to investors.
Several takeover candidates, including French investment fund PAI or American Advent, which spent 1.9 billion euros to acquire Sanofi’s former generics subsidiary Zentiva in 2018, will submit indicative takeover offers in mid-July.
1722497999
#Doliprane #sale #creates #friction #Sanofi #Bercy
